Sanofi announced that Dr. John Reed, its Global Head of R&D, will be leaving the company to pursue a new opportunity outside Sanofi. The company warmly thanks Dr. Reed for his leadership over these last years. Since joining Sanofi in 2018, John has laid the foundation for the company’s R&D transformation. He...
In early 2023, Sanofi Ventures received a commitment from its parent company for an additional multi-year commitment. The capital will be increased to more than 750 million dollar for the "evergreen venture fund." This venture capital fund focuses on early-stage investments, co-creating companies and leading financing...
Pharmaceutical company Sanofi has presented strong results for the first quarter of 2022. Sales grew by around 13 percent to 9.7 billion euros. Exchange rate fluctuations had a positive impact, mainly due to the dollar. Overall, the French company benefited from good business with its neurodermatitis and asthma drug...
Sanofi has named four new leaders to its Executive Committee. These appointments now complete the announced changes in February to further simplify the Company’s executive leadership team. The complete Sanofi Executive Committee now includes the four heads of the Company’s global business units (Sanofi Genzyme, Sanofi...
Sanofi Pasteur, the vaccines global business unit of Sanofi, will leverage previous development work for a Sars vaccine which may unlock a fast path forward for developing a Covid-19 vaccine. Sanofi will collaborate with the Biomedical Advanced Research and Development Authority (Barda), part of the Office of the...
Sanofi and Alnylam have agreed to conclude the research and option phase of the companies' 2014 RNAi therapeutics alliance in rare genetic diseases. The material collaboration terms for patisiran, vutrisiran (ALN-TTRsc02) and fitusiran, as previously announced, will continue unchanged.
